Physician profile
Ashraf Raslan
NPI 1023375649
$5,322.80
in general payments reported to CMS, 2019-2025
22 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $482 · 2021: $908 · 2022: $1,131 · 2023: $447 · 2024: $907 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519 · Education: $31.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.93 |
| Education | $31.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,499.59 | 2020-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $1,002.13 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $766.19 | 2019-2025 | Orencia |
| Ucb, INC. | $358.98 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $258.86 | 2019-2025 | |
| Janssen Biotech, INC. | $211.09 | 2024-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $196.69 | 2024-2025 | |
| Glaxosmithkline, LLC. | $194.80 | 2021-2025 | Benlysta |
| Genentech USA, INC. | $176.35 | 2019-2025 | Actemra, Gazyva |
| Lilly USA, LLC | $167.44 | 2022-2024 | Taltz |
| Aurinia Pharma U.S., INC. | $120.51 | 2021-2022 | |
| Horizon Therapeutics Plc | $95.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.08 | 2021-2025 | |
| Sobi, INC | $59.74 | 2022-2025 | |
| Organon LLC | $45.51 | 2022-2025 | Hadlima, Renflexis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $27.91 | 2021-2022 | |
| Johnson & Johnson Health Care Systems INC. | $16.89 | 2024 | Tremfya |
| Radius Health, INC. | $15.30 | 2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2022 | |
| Genzyme Corporation | $13.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Raslan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.